BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1897341)

  • 1. Comparison of North American and European malignant hyperthermia group halothane contracture testing protocols in swine.
    Fletcher JE; Conti PA; Rosenberg H
    Acta Anaesthesiol Scand; 1991 Aug; 35(6):483-7. PubMed ID: 1897341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
    Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
    Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group.
    Allen GC; Fletcher JE; Huggins FJ; Conti PA; Rosenberg H
    Anesthesiology; 1990 Jan; 72(1):71-6. PubMed ID: 2297135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of European and North American malignant hyperthermia diagnostic protocol outcomes for use in genetic studies.
    Fletcher JE; Rosenberg H; Aggarwal M
    Anesthesiology; 1999 Mar; 90(3):654-61. PubMed ID: 10078664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
    Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
    Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.
    Nelson TE; Bedell DM; Jones EW
    Anesthesiology; 1975 Mar; 42(3):301-6. PubMed ID: 1115384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Porcine malignant hyperthermia: false negatives in the halothane test.
    Gallant EM; Rempel WE
    Am J Vet Res; 1987 Mar; 48(3):488-91. PubMed ID: 3565905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
    Hopkins PM; Ellis FR; Halsall PJ
    Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.
    Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyfort GH; Dupuis BA
    Br J Anaesth; 1990 Jan; 64(1):64-6. PubMed ID: 2302378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
    Urwyler A; Censier K; Kaufmann MA; Drewe J
    Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound Elastography for Rapid, Real-time Detection of Localized Muscular Reaction in Malignant Hyperthermia-susceptible Pigs.
    Johannsen S; Türkmeneli I; Isbary S; Roewer N; Schuster F
    Anesthesiology; 2018 Nov; 129(5):989-999. PubMed ID: 30204593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility.
    Baur CP; Bellon L; Felleiter P; Fiege M; Fricker R; Glahn K; Heffron JJ; Herrmann-Frank A; Jurkat-Rott K; Klingler W; Lehane M; Ording H; Tegazzin V; Wappler F; Georgieff M; Lehmann-Horn F
    Anesth Analg; 2000 Jan; 90(1):200-5. PubMed ID: 10625004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
    Allen GC; Larach MG; Kunselman AR
    Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
    Ellis FR; Halsall PJ; Hopkins PM
    Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between the European and North American protocols for diagnosis of malignant hyperthermia susceptibility in humans.
    Islander G; Twetman ER
    Anesth Analg; 1999 May; 88(5):1155-60. PubMed ID: 10320187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.